Literature DB >> 26621475

Acetoacetate promotes the formation of fluorescent advanced glycation end products (AGEs).

Mousa Bohlooli1, Mansour Ghaffari-Moghaddam2, Mostafa Khajeh2, Zohre Aghashiri2, Nader Sheibani3, Ali Akbar Moosavi-Movahedi4.   

Abstract

Acetoacetate (AA) is an important ketone body, which produces reactive oxygen species (ROS). Advanced glycation end products (AGEs) are defined as final products of glycation process whose production is influenced by the levels of ROS. The accumulation of AGEs in the body contributes to pathogenesis of many diseases including complications of diabetes, and Alzheimer's and Parkinson's disease. Here, we evaluated the impact of AA on production of AGEs upon incubation of human serum albumin (HSA) with glucose. The effect of AA on the AGEs formation of HSA was studied under physiological conditions after incubation with glucose for 35 days. The physical techniques including circular dichroism (CD) and fluorescence spectroscopy were used to assess the impact of AA on formation and structural changes of glycated HSA (GHSA). Our results indicated that the secondary and tertiary structural changes of GHSA were increased in the presence of AA. The fluorescence intensity measurements of AGEs also showed an increase in AGEs formation. Acetoacetate has an activator effect in formation of AGEs through ROS production. The presence of AA may result in enhanced glycation in the presence of glucose and severity of complications associated with accumulation of AGEs.

Entities:  

Keywords:  acetoacetate; advanced glycation end products (AGEs); glycated HSA; prolonged incubation; reactive oxygen species (ROS), Ketone body

Mesh:

Substances:

Year:  2016        PMID: 26621475      PMCID: PMC5223773          DOI: 10.1080/07391102.2015.1125790

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  45 in total

Review 1.  Advanced glycation: an important pathological event in diabetic and age related ocular disease.

Authors:  A W Stitt
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

2.  Probing the interaction of human serum albumin with ciprofloxacin in the presence of silver nanoparticles of three sizes: multispectroscopic and ζ potential investigation.

Authors:  Hediyeh Iranfar; Omid Rajabi; Roshanak Salari; Jamshidkhan Chamani
Journal:  J Phys Chem B       Date:  2012-02-07       Impact factor: 2.991

Review 3.  Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes.

Authors:  L Laffel
Journal:  Diabetes Metab Res Rev       Date:  1999 Nov-Dec       Impact factor: 4.876

4.  The quantification of protein amino groups by the trinitrobenzenesulfonic acid method: a reexamination.

Authors:  P Cayot; G Tainturier
Journal:  Anal Biochem       Date:  1997-07-01       Impact factor: 3.365

5.  Acetone in uncontrolled diabetes.

Authors:  M J Sulway; E Trotter; M D Trotter; J M Malins
Journal:  Postgrad Med J       Date:  1971-06       Impact factor: 2.401

6.  Hyperketonemia can increase lipid peroxidation and lower glutathione levels in human erythrocytes in vitro and in type 1 diabetic patients.

Authors:  S K Jain; R McVie
Journal:  Diabetes       Date:  1999-09       Impact factor: 9.461

Review 7.  Advanced glycation endproducts--role in pathology of diabetic complications.

Authors:  Nessar Ahmed
Journal:  Diabetes Res Clin Pract       Date:  2005-01       Impact factor: 5.602

Review 8.  Nonenzymatic glycosylation and the pathogenesis of diabetic complications.

Authors:  M Brownlee; H Vlassara; A Cerami
Journal:  Ann Intern Med       Date:  1984-10       Impact factor: 25.391

9.  Plasma acid-base patterns in diabetic ketoacidosis.

Authors:  H J Adrogué; H Wilson; A E Boyd; W N Suki; G Eknoyan
Journal:  N Engl J Med       Date:  1982-12-23       Impact factor: 91.245

10.  Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites.

Authors:  N Iberg; R Flückiger
Journal:  J Biol Chem       Date:  1986-10-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.